Discontinued — last reported Q3 '25
Royalty Pharma Distributions from DIRECTV in Excess of Earnings increased by 747.1% to $42.31M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 16.7%, from $36.26M to $42.31M. Over 4 years (FY 2021 to FY 2025), Distributions from DIRECTV in Excess of Earnings shows an upward trend with a 276.6% CAGR.
Higher values indicate a return of capital, which may signal the investee is distributing cash beyond its current earnings capacity.
This metric tracks cash distributions received from an equity-method investment that exceed the company's share of the i...
Specific to companies with significant minority equity stakes in joint ventures or subsidiaries.
t_distributions_directv_excess_earnings| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $130.75K | $130.75K | $130.75K | $0.00 | $0.00 | $0.00 | $0.00 | $34.77M | $0.00 | $4.46M | $4.66M | $4.97M | $3.94M | $11.49M | $3.24M | $36.26M | $62.99M | $905.00K | $4.99M | $42.31M |
| QoQ Change | — | +0.0% | +0.0% | -100.0% | — | — | — | — | -100.0% | — | +4.5% | +6.6% | -20.6% | +191.4% | -71.8% | >999% | +73.7% | -98.6% | +451.8% | +747.1% |
| YoY Change | — | — | — | — | -100.0% | -100.0% | -100.0% | — | — | — | — | -85.7% | — | +157.7% | -30.3% | +630.4% | >999% | -92.1% | +53.9% | +16.7% |